0001610717-24-000122.txt : 20240304
0001610717-24-000122.hdr.sgml : 20240304
20240304174219
ACCESSION NUMBER: 0001610717-24-000122
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Symons Julian A.
CENTRAL INDEX KEY: 0001824727
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 24716610
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-03-01
0001799448
Aligos Therapeutics, Inc.
ALGS
0001824727
Symons Julian A.
C/O ALIGOS THERAPEUTICS, INC.
ONE CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
See Remarks
false
Stock Option (Right to Buy)
1.13
2024-03-01
4
A
0
72000
0
A
2034-03-01
Common Stock
72000
72000
D
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Executive Vice President, Chief Scientific Officer
/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons
2024-03-04